Why XOMA Stock Is Trading Higher Wednesday?

  • XOMA Corporation XOMA stock is trading higher during the morning session on robust volume after the FDA granted an Orphan drug tag to NIS793 for pancreatic cancer.
  • Under the terms of the 2015 agreement between XOMA and Novartis AG AG, XOMA can earn up to $445 million in additional milestone payments.
  • Yesterday, Novartis released the press release for NIS793 Orphan Drug Designation
  • Price Action: XOMA shares are up 11.6% at $37.39 during the market session on the last check Wednesday.
  • Related content: Benzinga's Full FDA Calendar.
Posted In: BiotechNewsHealth CareSmall CapFDAGeneralBriefsPancreatic Cancer